Zefen Xiao
Welcome,         Profile    Billing    Logout  
 6 Trials 
1 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xiao, Zefen
RATIONALE-311, NCT03957590: A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Completed
3
370
RoW
Tislelizumab, BGB-A317, Placebo, Paclitaxel, Cisplatin, Radiotherapy
BeiGene
Esophageal Squamous Cell Carcinoma (ESCC)
03/25
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xiao, Zefen
RATIONALE-311, NCT03957590: A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Completed
3
370
RoW
Tislelizumab, BGB-A317, Placebo, Paclitaxel, Cisplatin, Radiotherapy
BeiGene
Esophageal Squamous Cell Carcinoma (ESCC)
03/25
03/25

Download Options